|
|
Article: Callisto Announces First Berlin Issues Research Update Following Company's Announcement of New Data on Cancer Drug Efficacy; Independent German Based Equity Research Firm Maintains Buy Rating and Share Price Target of $2.50.
- Article from:
- Business Wire
- Article date:
- March 2, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced that a leading independent research firm, First Berlin Equity Research, has issued an updated research report projecting a $2.50 share price target, a "Buy" rating, and a speculative risk rating.
First Berlin issued the research update following Callisto's announcement that researchers in human clinical trials of its anti-cancer drug candidate Atiprimod found a "clear response" to reduce a class of solid cancer tumors called carcinoids. Treatment of metastatic carcinoid tumors is currently an ...